Journal
CATALYSTS
Volume 8, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/catal8020055
Keywords
rivastigmine; chemoenzymatic synthesis; bioreduction; whole-cell biocatalyst; (R)-arylethanols; baker's yeast; deep eutectic solvents
Categories
Funding
- University of Bari [Perna01333214Ricat]
- CIRCC consortia [COCM8470P0]
- C.I.N.M.P.I.S. consortia [COCM8470P0]
- Reti di Laboratori-Produzione Integrata di Energia da Fonti Rinnovabili nel Sistema Agroindustriale Regionale program - Apulia Region [01]
Ask authors/readers for more resources
Biocatalytic processes are increasingly playing a key role in the development of sustainable asymmetric syntheses, which are central to pharmaceutical companies for the production of chiral enantiopure drugs. This work describes a simple and economically viable chemoenzymatic process for the production of (S)-rivastigmine, which is an important drug for the treatment of mild to moderate dementia of the Alzheimer's type. The described protocol involves the R-regioselective bioreduction of an aromatic ketone by Lactobacillus reuteri DSM 20016 whole cells in phosphate buffered saline (PBS) (37 degrees C, 24 h) as a key step. Biocatalytic performance of baker's yeast whole cells in water and in aqueous eutectic mixtures have been evaluated and discussed as well. The route is scalable, environmentally friendly, and the target drug is obtained via four steps in overall 78% yield and 98% ee.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available